Oncolytics Biotech Inc (NASDAQ:ONCY) Q2 2020 Earnings Conference Call - Final Transcript
Aug 04, 2020 • 04:30 pm ET
Good day everyone and welcome to the Oncolytics Biotech's Second Quarter 2020 Earnings Conference Call. Today's conference is being recorded. [Operator Instructions] At this time, I'd like to turn the conference over to Tom Galassi of LifeSci Advisors. Please go ahead, sir.
Thank you, operator. Good afternoon, everyone, and welcome to Oncolytics Biotech's Second Quarter 2020 Conference Call. Earlier today, Oncolytics issued a press release providing their financial results and corporate updates for the second quarter of 2020. A replay of today's call will be available on the Investor Relations section of the Oncolytics website approximately two hours after its completion. After remarks from company management, we will open the call for Q&A.
As a reminder, various remarks made during this call about the company's future expectations, clients and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company's most recent Annual Report on Form 20-F, which is on file with the SEC. In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing their views as of any subsequent date. Except as required by law, Oncolytics specifically disclaims any obligation to update or revise any forward-looking statements even if the company's views change.
Now I will turn the call over to Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. Matt?
Thanks, Tom. And thanks to all listening for joining us on this call today to discuss our second quarter corporate update. Now in addition to Tom, I'm joined by Andrew de Guttadauro, our Global Head of Business Development; and Kirk Look, our Chief Financial Officer.
As I begin today's call, I'd like to say how incredibly proud I am of all the members of the Oncolytics team. Their talents and unwavering dedication has allowed us to make truly remarkable progress over the last quarter, particularly in light of the unpredictable and industry-wide challenges posed by the COVID-19 pandemic. Through the efficient implementation of a robust business continuity plan, Oncolytics is able to achieve five clinical milestones, including three data readouts in the second quarter. Completion of these milestones has proved important clinical validation of our unique Oncolytics virus immunotherapy platform, while also advancing our lead breast cancer program towards the initiation of a registrational study. Looking forward, we are well positioned to continue reporting a steady cadence of value-creating milestones across our diverse clinical pipeline.
Now I'd like to move on and provide some of our highlights from our productive quarter. We remain focused on the clinical advancement of pelareorep, our intravenously delivered immuno-oncolytic virus, towards a registrational study in HR+/HER2- metastatic breast cancer. A substantial unmet need exists in this indication has currently approved therapies that are unable to produce a meaningful survival advantage for the